IGHE and allergic disease: Prophylactic immunotherapy using biodegradable nanoparticles with encapsulated alpha‐Gal prior to tick protein‐induced alpha‐Gal IgE sensitization activates Th2 cytokines and suppresses the production of alpha‐Gal sIgE associated with hypersensitivity reactions to enhance immune tolerance against alpha‐Gal sensitization. Accordingly, alpha‐Gal‐containing nanoparticles are a potential strategy for increasing alpha‐Gal‐specific immune tolerance through modifications of immune mechanisms associated with alpha‐Gal‐induced IgE‐mediated allergic reactions